Trade of the SELL JNJ · Shelley M Capito
Johnson & Johnson Common Stock
Mixed signals
| Inside their committee's jurisdiction |
|
32/32 |
| Isolated decision, not a bulk rebalance |
|
13/22 |
|
Small, thinly-followed company
Nobody needs inside information to buy a mega-cap.
|
|
0/10 |
| Committee chair or ranking member |
|
8/8 |
| Member's own account |
|
0/8 |
|
A name they had never held before
A first purchase is a decision; the ninth purchase of the same holding is a standing order.
|
|
0/8 |
|
Unusually large for this member
Against their own median trade, not an absolute threshold - and capped, because trades beyond 3x did worse, not better.
|
|
0/6 |
| Position size |
|
0/3 |
| Leveraged instrument (option) |
|
0/3 |
A high grade is not an allegation. Every input is public, and buying into an industry you work on daily is ordinary expertise. What the trade actually returned is deliberately excluded from this score and shown separately below.
It is also not a forecast. Measured across every settled trade, A-graded ones did not beat E-graded ones to any significant degree — the method page prints the table. This score says a trade looks like a decision rather than administration, and nothing more.
The filing it came from
filed in 27 days Within the 30-day notification window.
The position this closes
| Bought | Disclosed size | Held | Return | vs S&P |
|---|---|---|---|---|
| 03 Mar 2020 | $1,001 - $15,000 | 958 d | +31.1% | +3.5% |
What a follower should do: already closed.
The tracked position had already reached its twelve months and been sold on the calendar before this sale was disclosed, so there is nothing to act on.
Matched oldest-lot-first on disclosed value within this account. Filings give a range, never a share count, so the pairing reads the documents rather than reconstructing the portfolio.
This is a sale, and the strategy does not act on it. It records the member closing a position; it is not a short signal and not an instruction to sell. Exiting when members disclose selling, rather than at twelve months, cut in-remit alpha from +6.76% to +3.57% — a cost of 6.50 points on the trades it changed. See the method.
This filing disclosed 10 transactions in total, of which 9 share this trade date (17 Oct 2022).
Filed 13 Nov 2022 · source PDF
Price
52-week range $170.17 – $267.24. The marker is the entry: the first market open after this filing became public.
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular…
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Analyst range | $190 – $305 |
| Employees | 138,200 |
| Instrument | ST |
| Jurisdiction tags | healthcarepharma |
Inside this member's remit. Their committees cover defenseenergyhealthcareindustrialsmaterialstechnologytelecomtransportutilities
Expressing this with options
An illustration, not a recommendation: the nearest listed expiry to a twelve-month horizon, struck near the money. Chains are live — Yahoo publishes no historical chains, so this is priced today, not when the filing was made, and the move it describes may already have happened.
Loading chain…
Outcome
| Held | This trade | S&P 500 | Alpha |
|---|---|---|---|
| 1m | — | — | — |
| 3m | — | — | — |
| 6m | — | — | — |
| 12m 1yr | — | — | — |
| 18m | — | — | — |
| 24m | — | — | — |
| 36m | — | — | — |
| 48m | — | — | — |
| 60m 5yr | — | — | — |
Measured from the first open after disclosure — the earliest anyone reading this could have acted. The highlighted now row sits at its true place in the sequence, so where it falls tells you how long the position has run. The last 9 rows are blank because those windows have not closed yet: this trade was entered —, so anything longer than that is still running.
Other congressional trades in JNJ
| Grade | Date | Member | Side | Amount |
|---|---|---|---|---|
| C | 29 Jun 2026 | Thomas H. Kean Jr | sale partial | $1,001 - $15,000 |
| B | 09 Jun 2026 | Lloyd Doggett | purchase | $1,001 - $15,000 |
| C | 02 Jun 2026 | Thomas H. Kean Jr | sale partial | $1,001 - $15,000 |
| E | 30 Mar 2026 | Alan Armstrong | purchase | $1,001 - $15,000 |
| E | 27 Mar 2026 | Alan Armstrong | purchase | $15,001 - $50,000 |
| C | 26 Mar 2026 | Thomas H. Kean Jr | sale partial | $1,001 - $15,000 |
| E | 19 Mar 2026 | Richard Dean Dr McCormick | sale partial | $1,001 - $15,000 |
| E | 19 Mar 2026 | Richard Dean Dr McCormick | sale partial | $1,001 - $15,000 |
| B | 19 Mar 2026 | John Boozman | sale partial | $1,001 - $15,000 |
| B | 10 Mar 2026 | Lloyd Doggett | purchase | $1,001 - $15,000 |
| B | 23 Jan 2026 | Thomas H. Kean Jr | sale partial | $15,001 - $50,000 |
| E | 18 Dec 2025 | Julie Johnson | sale | $1,001 - $15,000 |
| B | 09 Dec 2025 | Lloyd Doggett | purchase | $1,001 - $15,000 |
| B | 20 Nov 2025 | Thomas H. Kean Jr | sale partial | $15,001 - $50,000 |
| E | 13 Nov 2025 | Julie Johnson | sale partial | $1,001 - $15,000 |
| E | 05 Nov 2025 | Richard Dean Dr McCormick | purchase | $1,001 - $15,000 |
| E | 31 Oct 2025 | Lisa McClain | sale | $1,001 - $15,000 |
| E | 30 Oct 2025 | Lisa McClain | sale | $1,001 - $15,000 |
| E | 30 Oct 2025 | Lisa McClain | purchase | $1,001 - $15,000 |
| E | 10 Oct 2025 | Jared Moskowitz | sale partial | $1,001 - $15,000 |
| E | 10 Oct 2025 | Jared Moskowitz | sale partial | $1,001 - $15,000 |
| E | 23 Sep 2025 | Valerie Hoyle | sale | $1,001 - $15,000 |
| D | 19 Aug 2025 | Kelly Louise Morrison | sale partial | $1,001 - $15,000 |
| E | 14 Aug 2025 | Julie Johnson | sale partial | $1,001 - $15,000 |
| E | 04 Aug 2025 | Lisa McClain | purchase | $1,001 - $15,000 |